About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

New risk factor for mouth cancer uncovered

Source: www.medicalnewstoday.com Author: Tim Newman, fact checked by Paula Field In some regions, mouth cancer incidence has risen. A recent study investigates a new risk factor for mouth cancer. In certain parts of the world, over the past couple of decades, mouth cancer rates have soared. For instance, in the United Kingdom, rates of mouth cancer have increased by 68 percent. They rose from eight cases per 100,0000 in 1992–1995 to 13 cases per 100,000 in 2012–2014. In the United States, mouth cancer and mortality rates have declined overall. However, when examined at a state level, the data reveal a more complex picture. For instance, mouth cancer deaths have risen significantly in Nevada, North Carolina, Iowa, Ohio, Maine, Idaho, North Dakota, and Wyoming. Some known risk factors for mouth cancer include smoking tobacco, drinking alcohol, human papillomavirus (HPV), and chewing betel quid, which is a mix of natural ingredients wrapped in a betel leaf that is popular in some parts of Southeast Asia. In India, mouth cancers are the most common cause of cancer-related deaths in men aged 30–69 years old. Scientists think that chewing betel quid could be responsible for many of these deaths. New risk factor for mouth cancer Although scientists have confirmed some risk factors, there is still much to learn about how and why mouth cancer affects certain individuals and not others. Recently, scientists set out to investigate another potential risk factor: air pollution. The researchers, funded by the Ministry of Science and Technology in Taiwan, [...]

2018-10-12T12:20:45-07:00October, 2018|Oral Cancer News|
Read More

HPV vaccine expanded for people ages 27 to 45

Source: www.nytimes.com Authors: Denise Grady and Jan Hoffman About 14 million women and men become infected with the human papillomavirus each year in the United States, according to the Centers for Disease Control and Prevention. CreditCreditKeith Bedford/The Boston Globe, via Getty Images The HPV vaccine, which prevents cervical cancer and other malignancies, is now approved for men and women from 27 to 45-years-old, the Food and Drug Administration said on Friday. The vaccine is Gardasil 9, made by Merck, and had been previously approved for minors and people up to age 26. It works against the human papillomavirus, HPV, which can also cause genital warts and cancers of the vulva, anus, penis and parts of the throat. The virus has many strains. It is sexually transmitted, and most adults encounter at least one strain at some point in their lives. The vaccine protects against nine strains, including those most likely to cause cancers and genital warts. “Today’s approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range,” Dr. Peter Marks, director of the F.D.A.’s Center for Biologics Evaluation and Research, said in a statement. The approval was based on a study in women ages 27 to 45, showing that an earlier version of the vaccine was highly effective in preventing persistent HPV infection, genital warts, vulvar and vaginal precancers, cervical precancers and cervical cancers related to the virus types covered by the vaccine. The vaccine’s effectiveness in men ages 27 to [...]

2018-10-07T18:38:18-07:00October, 2018|Oral Cancer News|
Read More

HPV16 vaccine yields added benefit in recurrent throat cancer

Source: www.medpagetoday.com Author: Ian Ingram, Deputy Managing Editor, MedPage Today Adding a tumor-specific vaccine to PD-1 checkpoint inhibition was safe and effective in HPV16-positive patients with recurrent or metastatic oropharyngeal cancer, a small phase II trial found. Among 24 patients treated with nivolumab (Opdivo) and the ISA101 long peptide vaccine, 22 of whom had oropharyngeal cancer, 33% responded and median overall survival was 17.5 months, Cornelis Melief, PhD, of ISA Pharmaceuticals in the Netherlands, reported here at the 4th annual Cancer Immunotherapy Conference. All eight of the responders had oropharyngeal cancer (36%), with two complete and six partial responses. The median duration of response among these patients was 10.3 months, and responses were seen in both platin- and cetuximab-refractory patients, and those refractory to both. Melief noted that one of the partial responders had total clearance of the primary tumor, but a solitary lung metastasis remained, but was stable at 2.5 years. Rate of overall survival at 6 and 12 months was 75% and 70%, respectively. The combination was well tolerated and safe, said Melief, with no increase in the rate of serious adverse events. A randomized trial is planned to confirm the findings. "The results of our trial are among the first clinical data to support the general concept of combining cancer vaccination with immune checkpoint blockade to enhance efficacy of vaccine-activated T cells in the immunosuppressive tumor environment," Melief's group wrote in JAMA Oncology, where the findings were also published. The findings compare favorably to outcomes in a [...]

2018-10-04T09:03:12-07:00October, 2018|Oral Cancer News|
Read More

Oral sex and ‘deep kissing’ linked to increase in HPV-positive head and neck cancer

Source: www.sbs.com.au Author: Amelia Dunn Jake Simpson was 22 when he started to get painful toothaches. Trips back and forth to the dentist couldn’t seem to fix the growing lump at the back of his mouth It came as a total surprise to Jake, his partner Carly, and their newborn son Noah, when oncologists in Brisbane told him he had stage four head and neck cancer, and would need to start treatment immediately. “We didn’t know what any of it meant. He was so young and healthy, we couldn’t believe it,” Carly said. Despite rigorous treatment and surgery that removed more than two-thirds of his tongue, Jake’s cancer was too aggressive and spread to his lungs. He died within eight months of his diagnosis. These cancers, known as oropharyngeal cancers in the back of the tongue and tonsils, are on the rise in young men, and are caused by the sexually transmitted disease HPV – human papillomavirus. While doctors believe it is most commonly passed on through oral sex, some argue it’s now as easy as ‘deep kissing’. “Jake wasn't tested for HPV because it was too aggressive from the day one, but that age bracket that he fell in, more than likely, the cause was HPV,” Carly said. HPV has been dubbed the ‘common cold’ of STDs. Over 80 per cent of Australian adults will get HPV at one point in their lives, and most will clear it without even knowing. But two particular strains, P16 and P18 are [...]

2018-10-02T07:41:21-07:00October, 2018|Oral Cancer News|
Read More

Youth vaping has soared in 2018, new data show

Source: www.wsj.com Authors: Betsy McKay and Jennifer Maloney Number of high schoolers who used e-cigarettes in the past 30 days has risen some 75% in 2018 Teen use of e-cigarettes has soared this year, according to new research conducted in 2018 that suggest fast-changing youth habits will pose a challenge for public-health officials, schools and parents. The number of high-school students who used e-cigarettes in the past 30 days has risen roughly 75% since last year, according to a person who has seen new preliminary federal data. That would equate to about three million, or about 20% of high-school students, up from 1.73 million, or 11.7% of high-school students in the most recently published federal numbers from 2017. Nearly a third of 13-to-18-year-olds who responded to a separate survey conducted by The Wall Street Journal with research firm Mercury Analytics said they currently vape. The new numbers offer a rare look at evolving teen vaping habits. Sales of e-cigarettes are expected nearly to double this year over 2017, and researchers have wondered how much of that increase is because of teen use. But there can be a long lag time between the collection of data and public reports. Most of the teens who vape said they are doing it for reasons other than to quit smoking, according to the Journal’s survey conducted in 49 states in May. More than half said they do it because they like the flavors that e-cigarette liquids come in and they think vaping is fun. [...]

2018-09-21T08:57:52-07:00September, 2018|Oral Cancer News|
Read More

RJR Slapped with $6.5M verdict over musician’s mouth cancer

Source: blog.cvn.com Author: Arlin Crisco R.J. Reynolds was hit with a $6.5 million verdict Tuesday for the part jurors found the company played in the mouth cancer a Florida musician developed after years of smoking. Harewood v. R.J. Reynolds, 2007-CA-46331. The award followed the Florida 11th Circuit Court jury’s conclusion that nicotine addiction and cigarettes caused the oral cancer doctors diagnosed Glenn Simmons with in 1995. Simmons, a bassist in bands throughout much of his life, began smoking as a teenager and smoked about a pack a day for decades. He died in 2003, at age 48, from complications related to cancer-related radiation therapy. Monday's verdict found Reynolds liable on fraud and conspiracy claims related to a sweeping scheme to hide the dangers of cigarettes. However, while jurors awarded Simmons' daughter, Hanifah Harewood $6.5 million in compensatory damages, they rejected a claim for punitives in the case. The case is one of thousands of Florida’s Engle progeny lawsuits against the nation’s tobacco companies. They stem from a 2006 Florida Supreme Court decision decertifying Engle v. Liggett Group Inc., a class-action tobacco suit originally filed in 1994. Although the state’s supreme court ruled that Engle progeny cases must be tried individually, it found plaintiffs could rely on certain jury findings in the original case, including the determination that tobacco companies had placed a dangerous, addictive product on the market and had conspired to hide the dangers of smoking through much of the 20th century. In order to be entitled to those [...]

2018-09-20T19:26:41-07:00September, 2018|Oral Cancer News|
Read More

HPV-related cancer rates outpace vaccinations

Source: www.ctpost.com Author: Cara Rosner, Conn. Health Cancers linked to the human papillomavirus, commonly called HPV, rose dramatically in a 15-year period, even as the rates of young people being vaccinated climbed, the Centers for Disease Control and Prevention reported. The 43,371 new cases of HPV-associated cancers reported nationwide in 2015 marked a 44 percent jump from the 30,115 cases reported in 1999, according to a CDC analysis. HPV vaccination rates have improved over the years, but not fast enough to stem the rise in cancers, the CDC said. Oropharyngeal, or throat, cancer was the most common HPV-associated cancer in 2015, accounting for 15,479 cases among males and 3,438 among females. HPV infects about 14 million people each year. Between 1999 and 2015 rates of throat and vulvar cancer increased, vaginal and cervical cancer rates declined, and penile cancer rates were stable, according to the CDC. “The (overall rise) seems to be mostly driven by oropharyngeal cancers,” said Dr. Sangini Sheth, assistant professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine. “Vaccination is key to preventing those cancers,” said Sheth, who also is an associate medical director and director of colposcopy and cervical dysplasia at Yale New Haven Hospital’s Women’s Center. “Oropharyngeal cancer is most common in men, and HPV vaccination rates, while they are rising in the U.S. and Connecticut, became routine for boys later (than girls). And the rate of vaccinations among boys has definitely lagged that of girls. Hopefully, we will see vaccinating our [...]

2018-09-19T08:54:39-07:00September, 2018|Oral Cancer News|
Read More

Men with more than two oral sex partners are more likely to contract HPV

Source: www.nzherald.co.nz Author: Rebecca Sullivan Men who have had more than two oral sex partners are "significantly" more likely to contract HPV, a viral infection that can develop into oesophageal cancer, a new study has found. HPV, or the human papillomavirus, causes about 20-25 per cent of oesophageal cancer cases, said Professor Shan Rajendra from UNSW's Ingham Institute. Men are three times more likely than women to contract HPV through oral sex. Smoking and drinking are also big risk factors causing oesophageal cancer, reports news.com.au. Actor Michael Douglas, who smoked and drank excessively, famously went public about the cause of his own oesophageal cancer after being diagnosed in August 2010. "This particular cancer is caused by HPV [human papillomavirus], which actually comes about from cunnilingus." Douglas, the husband of Catherine Zeta Jones, told The Guardian in 2013. "It's a sexually transmitted disease that causes cancer." The study was presented at the Gastroenterological Society's annual Australian Gastroenterology Week last weekend and was also published in the academic journal Diseases of the Oesophagus. "What we found was that if you had more than two oral sex partners in your lifetime, then you increase your risk of HPV-associated esophageal cancer significantly," Professor Rajendra said. "It's sexually transmitted. You swallow the virus and it gets absorbed by the body and gets into the lining of the oesophagus. In some people it doesn't get cleared by the immune system. In most people it gets cleared but if it doesn't get cleared it can cause cancers [...]

2018-09-16T06:53:52-07:00September, 2018|Oral Cancer News|
Read More

FDA to review application to modify health warning on Altria subsidiary’s smokeless tobacco product

Source: www.richmond.com Author: staff The U.S. Food and Drug Administration will review a request from an Altria Group Inc. subsidiary that wants to make the claim that a smokeless tobacco product is less dangerous than cigarettes. U.S. Smokeless Tobacco Co. said Friday that the FDA has agreed to do a substantive review of its “modified risk” application for Copenhagen Snuff Fine Cut. The company submitted the request for review earlier this year. The snuff company wants to be able to use the claim “If you smoke consider this: Switching completely to this product from cigarettes reduces risk of lung cancer.” The FDA requires smokeless tobacco products to carry statements that warn about the risk of mouth cancer, gum disease, tooth loss and addiction and that the product is not a safe alternative to cigarettes. The warnings are to be randomly rotated on packaging. “We filed this application because we think adult smokers looking for potential reduced risk alternatives to cigarettes should have accurate information about the relative risks of Copenhagen Snuff,” Joe Murillo, Altria Client Services senior vice president for regulatory affairs, said in a statement. The FDA defines modified risk tobacco products as tobacco products that are sold or distributed for use to reduce harm or the risk of tobacco-related disease associated with commercially marketed tobacco products. In the review process, the FDA’s Tobacco Products Scientific Advisory Committee vets the scientific claims and makes a recommendation. The FDA has reviewed more than 30 modified risk applications from tobacco companies [...]

2018-09-16T06:48:11-07:00September, 2018|Oral Cancer News|
Read More

Scientists map interactions between head and neck cancer and HPV virus

Source: medicalxpress.com Author: staff, Gladstone Institutes Human papillomavirus (HPV) is widely known to cause nearly all cases of cervical cancer. However, you might not know that HPV also causes 70 percent of oropharyngeal cancer, a subset of head and neck cancers that affect the mouth, tongue, and tonsils. Although vaccines that protect against HPV infection are now available, they are not yet widespread, especially in men, nor do they address the large number of currently infected cancer patients. Patients with head and neck cancer caused by HPV respond very differently to treatments than those whose cancer is associated with the consumption of tobacco products. The first group generally has better outcomes, with almost 80 percent of patients surviving longer than 5 years after diagnosis, compared to only 45-50 percent for patients with tobacco-related cancers. To better understand what might cause these differences, a team of scientists led by Nevan J. Krogan, Ph.D., senior investigator at the Gladstone Institutes, is taking a unique approach by focusing on the cancer-causing virus. They recently mapped the interactions between all HPV proteins and human proteins for the first time. Their findings are published today in the journal Cancer Discovery. "With our study, we identified several new protein interactions that were previously not known to cause cancer, expanding our knowledge of the oncogenic roles of the HPV virus" said Krogan, who is also a professor of cellular and molecular pharmacology at UC San Francisco (UCSF) and the director of the Quantitative Biosciences Institute (QBI) at [...]

2018-09-13T08:58:41-07:00September, 2018|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top